Whitebox Advisors’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Whitebox Advisors’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44K	Hold	400,000	–	–	﹤0.01%	522
2026 Q1	$24.2K	Hold	400,000	–	–	﹤0.01%	484
2025 Q4	$74.9K	Hold	400,000	–	–	﹤0.01%	361
2025 Q3	$87K	Hold	400,000	–	–	﹤0.01%	307
2025 Q2	$48.1K	Hold	400,000	–	–	﹤0.01%	302
2025 Q1	$52K	Buy	+400,000	New	+$56.2K	﹤0.01%	226

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Whitebox Advisors's DMAAR Position: Q2 2026 in Review

Whitebox Advisors held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q2 2026 at 400,000 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #522.

Whitebox Advisors first reported a position in DMAAR in Q1 2025 and has held it in 6 quarters since. The position peaked at $87K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

Whitebox Advisors held 400,000 shares of Drugs Made In America Acquisition Corp Rights worth $44K as of Q2 2026.
Whitebox Advisors left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q2 2026.
Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Whitebox Advisors's portfolio in Q2 2026, its #522 holding.
Whitebox Advisors first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 6 quarters since.
Whitebox Advisors's Drugs Made In America Acquisition Corp Rights position peaked at $87K in Q3 2025.
28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Whitebox Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.